VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

NameVRTXON

RankNo.3709

Market Cap$0.00

Fully Diluted Market Cap$0.00

Market Share%

Trading Vol/Market Cap (24H)0.00%

Circulation Supply0.35953858

Max Supply0

Total Supply0.35953858

Circulation Rate%

Issue Date--

The price at which the asset was first issued--

All-Time High466.35223147502205,2026-03-26

Lowest Price432.04959348516377,2026-03-27

Public BlockchainETH

IntroductionVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sector

Social Media

• Official Website
• Block Explorer

etfindex:mc_etfindex_sourceDisclaimer: Data provided by cmc and should not be considered as investment advice.